Literature DB >> 2624997

Radioimmunoassay for erythropoietin using anti-recombinant erythropoietin antibody with high affinity.

K Matsubara1, T Yoshimura, S Kamachi, M Fukushima, M Hino, H Morii.   

Abstract

A sensitive radioimmunoassay (RIA) for the detection of erythropoietin (EPO) was developed using anti-recombinant EPO antibody with high affinity. The sensitivity was 100 amol/tube (5 mIU/ml) and it was possible to detect a serum EPO level between 5 and 200 mIU/ml. This method enabled us to measure native EPO as well as recombinant EPO. With this method we determined serum EPO levels in healthy individuals and patients with chronic renal disease, rheumatoid arthritis and iron deficiency anemia. Values in patients with chronic renal disease were lower than those in healthy individuals, while values in patients with rheumatoid arthritis, or iron deficiency anemia were significantly higher than those in healthy individuals.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2624997     DOI: 10.1016/0009-8981(89)90040-5

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  3 in total

1.  Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment.

Authors:  Y Yoshida; N Anzai; H Kawabata; Y Kohsaka; M Okuma
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

2.  Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production.

Authors:  N Hayashi; H Kinoshita; E Yukawa; S Higuchi
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

3.  Pure red cell aplasia induced by anti-erythropoietin antibodies, well-controlled with tacrolimus.

Authors:  Koji Hashimoto; Makoto Harada; Yuji Kamijo
Journal:  Int J Hematol       Date:  2016-06-23       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.